Seres Therapeutics Inc. announced a corporate reorganization that includes pausing additional investment in its SER-155 Phase 2 study for allogeneic hematopoietic stem cell transplant (allo-HSCT) and shifting operational focus to earlier-stage pipeline programs targeting inflammatory and immune diseases. As part of the reorganization, the company will implement a workforce reduction of approximately 30% to reduce operating costs. These measures are expected to extend Seres' cash runway through the third quarter of 2026, while the company continues to seek funding for the SER-155 Phase 2 study and explores potential collaborations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.